CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new antifungal drugs to combat increasing resistance in fungal infections, which currently have limited treatment options. Researchers will identify novel drug targets and create broad-spectrum antifungal molecules to address multi-resistant pathogens, ultimately advancing these candidates…
Invasive fungal diseases are estimated to kill 1.5 million people each year.
The incidence of mortality has risen significantly across the EU over the last 20 years due to an expansion of at risk patient populations.
Given the obvious importance of these diseases it is perhaps surprising that only four classes of drug are available to treat systemic fungal infection.
The azole class of antifungals provide the front line role for most disease treatment but recently resistance has emerged and it i…
THE UNIVERSITY OF MANCHESTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Saarbrucken
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Tarragona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Uppsala
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, MANCHESTER
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
